UA93179C2 - Antibody that specifically binds to il-22ra antibodies and methods of using thereof - Google Patents

Antibody that specifically binds to il-22ra antibodies and methods of using thereof

Info

Publication number
UA93179C2
UA93179C2 UAA200509928A UA2005009928A UA93179C2 UA 93179 C2 UA93179 C2 UA 93179C2 UA A200509928 A UAA200509928 A UA A200509928A UA 2005009928 A UA2005009928 A UA 2005009928A UA 93179 C2 UA93179 C2 UA 93179C2
Authority
UA
Ukraine
Prior art keywords
antibody
specifically binds
antibodies
methods
mammal
Prior art date
Application number
UAA200509928A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Веньфен Сюй
Уейн Киндсвогель
Ясмин A. Чандрасекер
Стейси P. Диллон
Джойс M. Ленер
Энтони У. Сиадак
Паллавур B. Сивакумар
Маргарет Д. Myp
Original Assignee
Займоджинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займоджинетикс, Инк. filed Critical Займоджинетикс, Инк.
Publication of UA93179C2 publication Critical patent/UA93179C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a monoclonal antibody or fragment thereof that specifically binds to an antigenic epitope of human IL-22RA (zcytor 11), wherein the antibody reduces or neutralizes the activity of human IL-22. The invention further relates to a method for inhibiting IL-22-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors, a method for reducing IL-22-induced inflammation in mammal, a method for suppressing an inflammatory response in a mammal with inflammation comprising comparing the level of serum amyloid A protein prior to admininstering composition of an antibody and after said administering.
UAA200509928A 2003-03-24 2004-03-24 Antibody that specifically binds to il-22ra antibodies and methods of using thereof UA93179C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24

Publications (1)

Publication Number Publication Date
UA93179C2 true UA93179C2 (en) 2011-01-25

Family

ID=36819185

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200509928A UA93179C2 (en) 2003-03-24 2004-03-24 Antibody that specifically binds to il-22ra antibodies and methods of using thereof

Country Status (2)

Country Link
CN (2) CN1845937A (en)
UA (1) UA93179C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347657T3 (en) * 2003-03-24 2010-11-03 Zymogenetics, Inc. ANTIBODIES DIRECTED AGAINST IL-22RA AND ASSOCIATES OF UNION AND PROCEDURE OF USE IN INFLAMMATION.
EA026334B1 (en) * 2009-01-27 2017-03-31 БЕРГ ЭлЭлСи Use of vitamin d compound for preventing or reducing chemotherapy-induced neutropenia
CN104583238A (en) * 2012-08-31 2015-04-29 阿尔金-X有限公司 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP2177616B1 (en) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors

Also Published As

Publication number Publication date
CN1798768A (en) 2006-07-05
CN1798768B (en) 2013-05-08
CN1845937A (en) 2006-10-11

Similar Documents

Publication Publication Date Title
Han et al. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning
Sabag et al. Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria
Hashimoto et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma
Detlefsen et al. Deposition of complement C3c, immunoglobulin (Ig) G4 and IgG at the basement membrane of pancreatic ducts and acini in autoimmune pancreatitis
Granne et al. ST2 and IL-33 in pregnancy and pre-eclampsia
RU2007139452A (en) METHODS AND COMPOSITIONS FOR MODULATION OF HYPERSTABILIZED c-met
BG111004A (en) Antibodies that bind to human interleukin-18 and methods of production and use thereof
CR20130150A (en) PROTEINS OF THE UNION TO IL-12 / P40 (DIVISIONAL EXP. 9599)
BRPI0408705A (en) a method for producing an antibody to a polypeptide, antibody produced therein, antibody or antibody fragment that binds to a polypeptide, methods for reducing or inhibiting il-20 induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors, to reduce il-20 induced inflammation, to suppress an inflammatory response in an inflamed mammal, to treat a mammal afflicted with an inflammatory disease, to treat a pathological condition in a patient associated with il-20 activity
Eberhardt et al. Differential expression of inwardly rectifying K+ channels and aquaporins 4 and 5 in autoimmune uveitis indicates misbalance in Müller glial cell‐dependent ion and water homeostasis
JP6728047B2 (en) Treatment methods and compositions
UA87979C2 (en) Human monoclonal antibody that neutralizes monocyte chemo-attractant protein-1 (mcp-1)
Walraven et al. Healthy human second‐trimester fetal skin is deficient in leukocytes and associated homing chemokines
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
WO2006007853A3 (en) A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
Rosado et al. Expression of human leukocyte antigen-G in systemic lupus erythematosus
WO2005025604A3 (en) Use of hmgb and hmgb fragments to decrease specific immune response
WO2020112889A3 (en) Methods for treating dysregulated lipid metabolism
Mendonça et al. Renal transplantation outcomes: a comparative analysis between elderly and younger recipients
Shi et al. IL‐22 produced by Th22 cells aggravates atherosclerosis development in ApoE−/− mice by enhancing DC‐induced Th17 cell proliferation
WO2005013912A3 (en) Anti-fcrn antibodies for treatment of auto/allo immune conditions
ATE517340T1 (en) SETS OF DIGITAL ANTIBODIES DIRECTED AGAINST SHORT EPITOPES AND METHODS USING THEM
Dietschmann et al. Th2 cells promote eosinophil‐independent pathology in a murine model of allergic bronchopulmonary aspergillosis
JOP20220193A1 (en) Formulations of human anti-tslp antibodies and methods of using the same
Wee et al. Tissue-resident natural killer cells exacerbate tubulointerstitial fibrosis by activating transglutaminase 2 and syndecan-4 in a model of aristolochic acid-induced nephropathy